- FDA approves Roche's Lunsumio🔍
- Point|Counterpoint Bispecific Antibodies in Earlier Lines of Therapy ...🔍
- Bispecific Antibodies for the Treatment of B|Cell Lymphomas🔍
- MSK ASH 2023 Insights🔍
- MM Answers Now🔍
- Two targets🔍
- Spotlight on Immunotherapy🔍
- Bispecific antibodies are progressing in cancer clinical trials🔍
Learnings from FDA‐Approved Bispecific Antibodies in Oncology ...
The FDA approval is based on positive results from the phase II GO29781 study of Lunsumio in people with heavily pre-treated FL, including those ...
Point-Counterpoint Bispecific Antibodies in Earlier Lines of Therapy ...
Bispecific antibodies (BsAbs) are the newest FDA approved class of therapy for patients with relapsed/refractory multiple myeloma whose ...
Bispecific Antibodies for the Treatment of B-Cell Lymphomas
As of August 29, 2023, the FDA has approved 9 BsAbs, including 2 for non-oncology indications (hemophilia A and macular edema) and 7 BsAbs with ...
MSK ASH 2023 Insights: Promising Results for Bispecific Antibodies ...
The U.S. Food and Drug Administration (FDA) recently approved two CD20xCD3 bispecific antibodies —mosunetuzumab (mosun) for patients with ...
MM Answers Now: Are Bispecific Antibodies the Future?
Bispecific antibodies show great promise in relapsed/refractory multiple myeloma. ... Dr. Baljevic explains the recent approval by the U.S. Food ...
Two targets, one solution: The rise of bispecific antibodies - Labiotech
According to Her, the bispecific antibody landscape is rapidly evolving, with 12 bispecific antibodies currently approved by the FDA, and four ...
Spotlight on Immunotherapy: Pushing the Frontier of Cancer Medicine
T-cell engaging bispecific antibodies work by flagging cancer cells for destruction by the immune system. As of July 31, 2023, the FDA has approved six ...
Bispecific antibodies are progressing in cancer clinical trials
Currently, the only FDA-approved bispecific antibody for cancer therapy is blinatumomab, which is used in B-cell leukemia.
Bispecific Antibody Development Programs; Draft Guidance for ...
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Bispecific ...
Bispecifics antibodies: The next big thing in lymphoma treatment
Illustration of a bispecific antibody engaging T cell and cancer cell. Bispecific antibody engages CD20 antigen target on a cancer cell. CD20- ...
Later-Line CD19 and Bispecific Therapies Considered After CAR T
We currently have 2 FDA-approved bispecific antibodies in the third-line setting for relapsed/refractory DLBCL [with epcoritamab (Epkinly) and ...
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class ...
U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple ...
Expert Strategies for Recognition and Management of Adverse ...
With new developments in CD20 x CD3 bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), community oncology ...
Limited-duration bispecific antibody therapy for multiple myeloma
Bispecific antibodies are a new, highly effective immunotherapy for multiple myeloma. Most bispecific antibody therapies have been tested as continuous ...
EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First ...
"Epcoritamab is a subcutaneous bispecific antibody that offers an additional treatment option for this patient population. With this approval ...
The New Era of Bispecific Antibodies for Cancer Immunotherapy
As of 2022, 6 bsAbs had been approved by EMA and/or FDA in cancer immunotherapy (Table 1), including the first approved bsAb, Catumaxomab, which was withdrawn ...
A Hematologist explains bispecific antibodies in myeloma treatment
Jack: We have one bispecific antibody called teclistamab, also known as Tecvayli, that's currently FDA-approved. How is it given? Who is it ...
Tocilizumab, but not dexamethasone, prevents CRS without ...
Bispecific antibodies (bsAb) and chimeric antigen receptor (CAR) T cells allow for antibody guided recruitment of T cells against tumors. Both are ...
Linvoseltamab Still Efficacious Despite CRL in Multiple Myeloma
A complete response letter (CRL) was recently issued by the FDA for the BCMA bispecific antibody, linvoseltamab, for use in patients with ...
Tecvayli: First FDA-Approved Bispecific Antibody for Relapsed ...
On October 25, 2022, Tecvayli (teclistamab, Janssen Biotech, Inc.) received FDA approval as the first bispecific antibody for patients with RRMM ...